Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Bolt Biotherapeutics Inc
Healthcare
P/NCAV
0.72x
Ticker
BOLT
Exchange
NASDAQ
Country
United States
Close
1.11 $
Mkt Cap
42.0M $
EV
31.2M $
NCAV Burn Rate
49.6%
Current Ratio
5.17
Debt/Equity
0.0
EV/REV
3.96x
EV/EBIT
-0.4x
EV/FCF
-0.4x
Dilution
1.8% p.A
Total Net Income
-358.7M $
Cheapness
1.0%
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company-s pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average